136 related articles for article (PubMed ID: 28948575)
1. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
Amer AM; Allam AN; Abdallah OY
AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System.
de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J
AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and
Amer AM; Allam AN; Abdallah OY
Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
[TBL] [Abstract][Full Text] [Related]
5. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor.
Gurunath S; Nanjwade BK; Patil PA
Drug Dev Ind Pharm; 2015 Jan; 41(1):170-6. PubMed ID: 24168234
[TBL] [Abstract][Full Text] [Related]
8. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
9. Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids.
Borde AS; Karlsson EM; Andersson K; Björhall K; Lennernäs H; Abrahamsson B
Eur J Pharm Biopharm; 2012 Apr; 80(3):630-7. PubMed ID: 22155764
[TBL] [Abstract][Full Text] [Related]
10. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
11. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
[TBL] [Abstract][Full Text] [Related]
12. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934
[TBL] [Abstract][Full Text] [Related]
13. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.
Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE
Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332
[TBL] [Abstract][Full Text] [Related]
14. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media.
Hoppe K; Sznitowska M
AAPS PharmSciTech; 2014 Oct; 15(5):1116-25. PubMed ID: 24871550
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
16. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure.
Ferreirós N; Dresen S; Alonso RM; Weinmann W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Aug; 855(2):134-8. PubMed ID: 17478126
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of candesartan.
Gleiter CH; Mörike KE
Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
[TBL] [Abstract][Full Text] [Related]
18. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil microemulsions for transdermal delivery: formulation, in-vitro skin permeation and stability assessment.
Malakar J; Basu A; Nayak AK
Curr Drug Deliv; 2014; 11(3):313-21. PubMed ID: 24893994
[TBL] [Abstract][Full Text] [Related]
20. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil.
Ertürk AS; Gürbüz MU; Tülü M
Pharm Dev Technol; 2017 Feb; 22(1):111-121. PubMed ID: 27484586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
